依达拉奉联合奥扎格雷钠治疗急性进展性脑梗死的临床效果分析

Analysis of the Clinical Effect of Edaravone Combined with Ozagrel in the Treatment of Acute Progressive Cerebral Infarction

目的探讨依达拉奉联合奥扎格雷钠治疗急性进展性脑梗死的临床效果。方法本次研究选取对象共68例,均为本院2016年9月至2017年11月所接收的急性进展性脑梗死患者,分组采用数字表分组法,对照组患者采用接受的治疗方法主要为单纯使用奥扎格雷钠,治疗组患者则是在对照组患者所接受治疗方法的基础上联合使用依达拉奉,对比两组治疗效果。结果两组患者在接受治疗1周后,在疾病控制改善程度上,治疗组患者治疗效果91.18%,明显高于对照组患者的治疗效果73.53%,且两组之间差异较为显著,即χ~2=4.678,P<0.05。两组患者在接受治疗2周后,以NIHSS评分的改善评价治疗效果,治疗组患者最终的治疗效果94.12%,明显高于对照组患者治疗效果82.35%,且两组之间差异较为显著,即χ~2=6.403,P<0.05。结论对于急性进展性脑梗死而言,将依达拉奉与奥扎格雷钠联合治疗可以有效控制患者病情并且明显改善患者的神经功能缺损程度,具有较高的应用价值,值得推广使用。

Objective To investigate the clinical effect of edaravone combined with ozagrel in the treatment of acute progressive cerebral infarction. Methods This study selected subjects a total of 68 cases, all patients in our hospital from September 2016 to November 2017 with acute cerebral infarction of the received packet, using digital table grouping method, control group received the treatment method for the simple use of ozagrel sodium, the patients in the treatment group is in the control treatment group patients accepted again receive edaravone, compare the efficacy of two groups. Results Two groups of patients after receiving treatment for 1 week, on the degree of disease treatment, the treatment group's treatment effect was 91.18%, which was significantly higher than that of the control group. The final treatment effect was 73.53%, and the difference between the two groups was more significant,χ^2=4.678, P <0.05. Two groups of patients in 2 weeks after treatment, in the treatment of NIHSS score, the final treatment effect of the treatment group was 94.12%, which was significantly higher than that of the control group. The final treatment effect was 82.35%, and the difference between the two groups was more significant,χ^2=6.403, P <0.05. Conclusion For acute progressive cerebral infarction, edaravone combined with ozagrel can effectively control the patient's condition and improve the degree of neurological deficit. It has high application value and is worth promoting.